

## PRODUCT INFORMATION SHEET

### Monoclonal antibodies detecting human antigens

#### TNF- $\alpha$

PURE	<span style="border: 1px solid black; padding: 2px;">RUO</span>	<span style="border: 1px solid black; padding: 2px;">REF</span>	IQP-163P	▽	50 tests
R-PE	<span style="border: 1px solid black; padding: 2px;">RUO</span>	<span style="border: 1px solid black; padding: 2px;">REF</span>	IQP-163R	▽	50 tests

RUO **For Research Use Only**



#### Description

**Clone** B-C7

**Isotype** Murine IgG1

**Specificity** Clone B-C7 produces mouse IgG1 immunoglobulins directed against human TNF- $\alpha$ , a 17 kD molecular weight protein. It blocks TNF- $\alpha$  activity on the L929 cell line. Anti-TNF- $\alpha$  (clone B-C7) recognizes both natural and recombinant human TNF- $\alpha$  and TNF- $\alpha$  bound to its receptor.

#### Antigen distribution

Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) is a cytokine expressed by a number of cell types including activated lymphocytes (T and B cells), monocytes/macrophages, NK cells and LAK cells. Previously, TNF- $\alpha$  was known as cachectin. TNF- $\alpha$  is capable of killing tumor cells directly. In addition, TNF- $\alpha$  can elicit a variety of cytokines involved in anti-tumor and inflammatory responses.

#### Summary

The immune system reacts to a pathogen by activation of a balanced network of the humoral and cellular immune responses. Subsequently the activated condition of the immune system will, after the elimination of the pathogen, be down-regulated to a balanced situation again. Control of the immune response requires efficient communication between the different cells involved in this response. This interaction is provided by cell/cell contact and by a complex array of mediators. Among these mediators cytokines, soluble factors produced by these cells, play an important role.

Cytokines can act on other cells locally or distantly, but can be even auto-regulating. Cytokines can behave stimulatory or inhibitory, or can even perform both activities, depending on the (pre)activation stage of the target cell.

Lymphocytes play an important role in antigen-specific immune-responses. Much interest is focusing on the activity of T helper cells. Within this population of white blood cells, cells are defined on the bases of the cytokine pattern they express and actions they take. Two of the extremes in this spectrum of T helper cells are T<sub>H</sub>1 cells and T<sub>H</sub>2 cells.

T<sub>H</sub>1 cells are involved in cell-mediated immune responses, while T<sub>H</sub>2 cells have an important role in humoral immune-responses. Both T helper cell types express CD3 and CD4 antigens, and no further differentiation can be made immuno-phenotypically. However, functionally, these cells can be distinguished based on the cytokines produced by each subtype. Production of a selected number of cytokines by T cells is illustrated in table 1. Both T<sub>H</sub>1 cells and T<sub>H</sub>2 cells develop from a mutual precursor the naive T helper cell, which doesn't produce many types of cytokines. Upon stimulation, the right co-stimulation and messengers (like cytokines) the naive T helper cell is skewed into the direction of an effector T helper cell in the spectrum mentioned.

Table 1 - Production of cytokines by human T helper cells type 1 and 2

<i>Cytokine</i>	<i>T helper 1 cells</i>	<i>T helper 2 cells</i>
IL-2	++	+
IFN- $\gamma$	++	-
TGF- $\beta$	++	-
TNF- $\alpha$	++	-
IL-4	-	++
IL-5	-	++
IL-13	-	++
IL-3	+/-	+
IL-6	+/-	+
IL-10	+/-	+

Clinically T<sub>H</sub>1 and T<sub>H</sub>2 cells play an important role in a variety of diseases. As stated above, T<sub>H</sub>1 cells appear to be involved in cell-mediated immune responses like in bacterial infections, development of auto-immune diseases and transplant rejection. Whereas, T<sub>H</sub>2 cells appear to be involved in immune protection in response to allergens, but may also lead to allergenic reactivity. Furthermore, development of progressive disease in patients with HIV infection, may be accompanied by a shift from a T<sub>H</sub>1 cell response to a T<sub>H</sub>2 cell response. These findings can be important for the therapeutic approach of HIV during disease.

## Principles of the Procedure

The level of most of the cytokines produced by immune unstimulated cells is too low to be detected by flow cytometry analysis. After stimulation the level of cytokines is rising and depending on the way of stimulation, the cell population, the secretion inhibitor that is used and several other factors several cytokines are upregulated and in detectable concentrations present. Therefore, a method has been developed to analyze cells which have been stimulated to make detection of these intracellularly expressed cytokines possible.

The by IQ Products developed Cytodetect™ kit (IQP-366) provides reagents for cell stimulation, fixation and permeabilization. The kit also comes with three detailed protocols.


Reagents provided in the Cytodetect™ kit allow processing of 50 blood samples. Each sample can be further analyzed for five (5) different intracellular antigens using one step PE-labeled immuno conjugates, followed by flow cytometry.

## Usage

All these reagents are effectively formulated for direct immunofluorescent staining of human tissue for flow cytometric analysis using  $10 \mu\text{l}/10^6$  leukocytes for singles and  $20 \mu\text{l}/10^6$  leukocytes in case of dual and triple combinations. Since applications vary, each investigator should titrate the reagent to obtain optimal results.

## Representative Data

Clone B-C7 (anti-TNF- $\alpha$ ), was analyzed by flow cytometry according to the Cytodetect™ Kit protocol peripheral blood leukocytes were isolated from a blood sample obtained from a healthy volunteer, and subsequently stimulated, fixed and permeabilized. Direct staining was performed using  $10 \mu\text{l}$  of the PE-conjugated monoclonal antibody preparation per sample.



## Limitations

1. Conjugates with brighter fluorochromes, like PE and APC, will have a greater separation than those with dyes like FITC and CyQ. When populations overlap, the percentage of positive cells using a selected marker can be affected by the choice of fluorescent label.
2. Use of monoclonal antibodies in patient treatment can interfere with antigen target recognition by this reagent. This should be taken into account when samples are analyzed from patients treated in this fashion. IQ Products has not characterized the effect of the presence of therapeutic antibodies on the performance of this reagent.
3. Reagents can be used in different combinations, therefore laboratories need to become familiar performance characteristics of each antibody in relation with the combined markers in normal and abnormal samples.
4. Reagent data performance is based on EDTA-treated blood. Reagent performance can be affected by the use of other anticoagulants.

## Reagents and materials required but not supplied

1. Flow cytometer
2. Flow cytometry disposable  $12 \times 75$ -mm capped polystyrene test tubes
3. Micropipette with disposable tips
4. Vortex mixer
5. Centrifuge
6. PBS (phosphate-buffered saline)
7. 1% paraformaldehyde solution in PBS (store at  $2-8^\circ\text{C}$  in amber glass for up to 1 week)

## **Test Procedure**

**Note:** Unless stated otherwise reagents (including PBS) should be at room temperature when used.

### 1. *Isolation of blood lymphocytes*

- Collect 5 - 10 ml venous blood into a heparinized tube or EDTA-treated tube, using aseptic venipuncture technique. Process the blood sample within 6 hours of sample collection. In patients with severe neutropenia (absolute neutrophil count less than 200/mm<sup>3</sup>) at least 10 ml of blood may be required.
- Dilute blood sample 1:1 with PBS (Phosphate Buffered Saline).
- Add Ficoll-Paque (5 ml) in a centrifuge tube.
- Carefully layer 5 ml of the diluted blood sample on 5 ml of Ficoll-Paque.
- Centrifuge at 600 g for 20 minutes.
- Transfer the lymphocyte layer to a clean centrifuge tube.
- Add 5 ml of HBSS and centrifuge at 400 g for 15 minutes.
- Remove the supernatant and add 10 ml of RPMI 1640.
- Centrifuge at 300 g for 10 minutes and remove the supernatant.
- Resuspend the cells in RPMI 1640 to a concentration of 2 x 10<sup>6</sup> cells/ml.
- 1 ml of cell suspension is sufficient for intracellular detection of 5 different cytokines; make sure that besides stimulated cells also unstimulated controls are available.

### 2. *Stimulation of cells*

- Put 1 ml of the cell suspension into a 24 wells culture plate and add appropriate stimulus and a secretion inhibitor, like Brefeldin A or Monensin. Mix carefully with a pipette.
- Incubate for 5 hours at 37 °C, 5% CO<sub>2</sub>.

**Note:** 5 hours of incubation are suggested in the Cytodetect™ kit. This is an average; the optimal stimulation time has to be determined by the user. The optimum can differ because of the state of cells and kind of cells.

- After stimulation transfer the cells to a centrifuge tube and add 5 ml of HBSS.
- Centrifuge at 300 g for 10 minutes and remove the supernatant.

### 3. *Fixation of cells*

- Add 500 µl of cold (4 °C) fixative and incubate for 10 minutes at room temperature.
- Add 9 ml of HBSS and centrifuge at 300 g for 10 minutes.
- Remove the supernatant and resuspend the cells in 500 µl of HBSS.
- Cells can be stored overnight at 4 °C or processed further.

### 4. *Staining of cell surface antigens*

- When cells have been stored overnight in the refrigerator please wash once with 5 ml HBSS. Resuspend the pellet after removing the supernatant in 500 µl of HBSS again.
- Add 10 µl of monoclonal antibody conjugate of choice *against surface* antigen to a 3 ml flow cytometer tube.
- Add 100 µl of cell suspension to the tube and mix well by vortexing, and incubate for 20 minutes at room temperature in the dark.

### 5. *Permeabilization of cells*

- Add 1.5 ml of permeabilization solution.
- Centrifuge at 200 g for 5 minutes.
- Remove the supernatant and resuspend the cells in 500 µl of permeabilization solution, use 100 µl for staining of intracellular antigens.

### 6. *Staining of intracellular antigens*

- Add 10 µl of R-PE conjugated monoclonal antibody against intracellular antigens to the reagent tube, and mix well by vortexing.
- Incubate for 20 minutes at 4 °C in the dark.
- Add 1.5 ml of permeabilization solution and centrifuge at 200 g for 5 minutes.
- Remove the supernatant and resuspend the cells in 100 - 300 µl of HBSS.

### 7. *Analysis by flow cytometry*

- Analyze the cells by flow cytometry.
- Use appropriate controls for immunostaining and data processing.



### Handling and Storage

Antibodies are supplied as 50 tests per vial (0.5 ml). They are supplied in 0.01 M sodium phosphate, 0.15 M NaCl; pH 7.3, 0.2% BSA, 0.09% sodiumazide (NaN<sub>3</sub>). Store the vials at 2-8 °C. Monoclonal antibodies should be protected from prolonged exposure to light. Reagents are stable for the period shown on the vial label when stored properly.

**Warranty** Products sold hereunder are warranted only to conform to the quantity and contents stated on the label at the time of delivery to the customer. There are no warranties, expressed or implied, which extend beyond the description on the label of the product. IQ Products is not liable for property damage, personal injury, or economic loss caused by the product.

### Characterization

To ensure consistently high-quality reagents, each batch of monoclonal antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.















**Warning** All products contain sodiumazide. This chemical is poisonous and hazardous. Handling should be done by trained staff only.

---

### References

1. Moore JS, Zaki MH. Clinical cytokine network cytometry. *Clin Lab Med* 2001 Dec; 21(4):795-809.
2. Santiago MA, Luca PM, Bertho AL, Azeredo-Coutinho RB, Coutinho SG. Detection of intracytoplasmic cytokines by flow cytometry. *Mem Inst Oswaldo Cruz* 2000 May-Jun; 95(3): 401-2.
3. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. *Biochem Biophys Res Commun* 2002 Oct 4; 297(4): 700-13.
4. Townsend MJ, McKenzie AN. Unravelling the net? Cytokines and diseases. *J Cell Sci* 2000 Oct; 113 (Pt 20): 3549-50.
5. Prussin C. Cytokine flow cytometry: understanding cytokine biology at the single-cell level. *J Clin Immunol* 1997 May; 17(3): 195-204.
6. Pala P, Hussell T, Openshaw PJ. Flow cytometric measurement of intracellular cytokines. *J Immunol Methods* 2000 Sep 21; 243(1-2): 107-24.
7. Pala P, Hussell T, Openshaw PJ. Flow cytometric measurement of intracellular cytokines. *Immunol Methods* 2000 Sep 21; 243(1-2): 107-24.
8. Romagnani S. T-cell subsets (Th1 versus Th2). *Ann Allergy Asthma Immunol* 2000 Jul; 85(1):9-18.
9. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. *Int Rev Immunol* 1998; 16(3-4): 427-55.
10. Infante-Duarte C, Kamradt T. Th1/Th2 balance in infection. *Springer Semin Immunopathol* 1999; 21(3): 317-38.
11. Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, Hoelzer D, Rossol R. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. *AIDS* 1997 Jul 15; 11(9): 1111-8.
12. Blesing JJ, Fleisher TA. Cell function-based flow cytometry. *Semin Hematol* 2001 Apr; 38(2): 169-78.
13. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. *Transplantation* 2002 May 15; 73(9): 1373-8.
14. Zhai Y, Ghobrial RM, Busuttill RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost? *Crit Rev Immunol* 1999; 19(2): 155-72.
15. Girolomoni G, Sebastiani S, Albanesi C, Cavani A. T-cell subpopulations in the development of atopic and contact allergy. *Curr Opin Immunol* 2001 Dec; 13(6): 733-7.
16. Kapsenberg ML, Hilkens CM, Jansen HM, Bos JD, Sniijders A, Wierenga EA. Production and modulation of T-cell cytokines in atopic allergy. *Int Arch Allergy Immunol* 1996 Jun; 110(2): 107-13.
17. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. *J Immunol* 1999 Mar 15; 162(6): 3718-26.
18. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA, Picker LJ. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. *J Virol* 2001 Dec; 75(24): 11983-91.
19. Rostaing L, Tkaczuk J, Durand M, Peres C, Durand D, de Preval C, Ohayon E, Abbal M. Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. *Cytometry* 1999 Apr 1; 35(4): 318-2.

### Explanation of used symbols

	Consult instructions for use
	Catalogue number
	Sufficient for
	In Vitro Diagnostic medical device
	Caution, consult accompanying document
	Keep away from (sun)light
	Biological risks
	Temperature limitation (°C)
	For Research Use Only
	Batch code
	Use by yyyy-mm-dd
	Manufacturer
	Authorized Representative in the European Community
	Conformité Européenne (European Conformity)

		<b>Label - tandem</b>	<b>Ex -max (nm)</b>	<b>Em -max (nm)</b>
P	PURE	purified material	-	-
F	FITC	FITC	488	519
R	R-PE	PE	488, 532	578
C	CyQ	PE-Cy5.18	488, 532	667
A	APC		595, 633, 635, 647	660
PC	PerCP		488, 532	678
PCC	PerCP-Cy5.5		488, 532	695



IQ Products BV  
Rozenburglaan 13a  
9727 DL Groningen, The Netherlands

 +31 (0)50 57 57 000  
 +31 (0)50 57 57 002  
 Technical [marketing@iqproducts.nl](mailto:marketing@iqproducts.nl)  
 Orders [orders@iqproducts.nl](mailto:orders@iqproducts.nl)  
 [www.iqproducts.nl](http://www.iqproducts.nl)